Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation

Brian Latimer, Oleksandr Ekshyyan, Neil Nathan, Tara Moore-Medlin, Xiaohua Rong, Xiaohui Ma, Alok Khandelwal, Hunter T. Christy, Fleurette Abreo, Gloria McClure, John A. Vanchiere, Gloria Caldito, Tammy Dugas, Kenneth McMartin, Timothy Lian, Vikas Mehta, Cherie Ann O Nathan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background/Aim: Curcumin is a promising nutraceutical for chemoprevention of head and neck squamous cell carcinoma (HNSCC). Capsular formulations of curcumin demonstrate low systemic bioavailability. We aimed to determine if curcumin levels were higher in healthy volunteers and cancer patients with microgranular curcumin that allows for transmucosal absorption and identify a consistent biomarker. Patients and Methods: Eight healthy volunteers and 15 HNSCC patients completed the trials. Serum levels of curcumin were measured by HPLC. Biological activity of curcumin was assessed with Multiplex Immunoassay and immunohistochemistry. Results: We achieved higher serum levels of curcumin compared to trials using capsular formulation. In cancer patients a significant decrease in expression of fibroblast growth factor-2 (FGF-2) in post-biopsy samples and decreased serum levels of FGF- 2, granulocyte macrophage colony-stimulating factor (GMCSF) and interleukin-17 (IL-17) (p<0.05) was observed. Conclusion: Transmucosal administration of microgranular curcumin leads to enhanced curcumin bioavailability that is associated with significant biological effects.

Original languageEnglish (US)
Pages (from-to)6411-6418
Number of pages8
JournalAnticancer Research
Volume35
Issue number12
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Mucosal Administration
Curcumin
Biological Availability
Fibroblast Growth Factor 2
Healthy Volunteers
Serum
Interleukin-17
Chemoprevention
Granulocyte-Macrophage Colony-Stimulating Factor
Dietary Supplements
Immunoassay
Neoplasms
Biomarkers
Immunohistochemistry
High Pressure Liquid Chromatography

Keywords

  • Bioavailability
  • Curcumin
  • Head and neck squamous cell carcinoma
  • Microgranules

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Latimer, B., Ekshyyan, O., Nathan, N., Moore-Medlin, T., Rong, X., Ma, X., ... Nathan, C. A. O. (2015). Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation. Anticancer Research, 35(12), 6411-6418.

Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation. / Latimer, Brian; Ekshyyan, Oleksandr; Nathan, Neil; Moore-Medlin, Tara; Rong, Xiaohua; Ma, Xiaohui; Khandelwal, Alok; Christy, Hunter T.; Abreo, Fleurette; McClure, Gloria; Vanchiere, John A.; Caldito, Gloria; Dugas, Tammy; McMartin, Kenneth; Lian, Timothy; Mehta, Vikas; Nathan, Cherie Ann O.

In: Anticancer Research, Vol. 35, No. 12, 01.12.2015, p. 6411-6418.

Research output: Contribution to journalArticle

Latimer, B, Ekshyyan, O, Nathan, N, Moore-Medlin, T, Rong, X, Ma, X, Khandelwal, A, Christy, HT, Abreo, F, McClure, G, Vanchiere, JA, Caldito, G, Dugas, T, McMartin, K, Lian, T, Mehta, V & Nathan, CAO 2015, 'Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation', Anticancer Research, vol. 35, no. 12, pp. 6411-6418.
Latimer B, Ekshyyan O, Nathan N, Moore-Medlin T, Rong X, Ma X et al. Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation. Anticancer Research. 2015 Dec 1;35(12):6411-6418.
Latimer, Brian ; Ekshyyan, Oleksandr ; Nathan, Neil ; Moore-Medlin, Tara ; Rong, Xiaohua ; Ma, Xiaohui ; Khandelwal, Alok ; Christy, Hunter T. ; Abreo, Fleurette ; McClure, Gloria ; Vanchiere, John A. ; Caldito, Gloria ; Dugas, Tammy ; McMartin, Kenneth ; Lian, Timothy ; Mehta, Vikas ; Nathan, Cherie Ann O. / Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation. In: Anticancer Research. 2015 ; Vol. 35, No. 12. pp. 6411-6418.
@article{48242ee87f6641de976c1005455cce59,
title = "Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation",
abstract = "Background/Aim: Curcumin is a promising nutraceutical for chemoprevention of head and neck squamous cell carcinoma (HNSCC). Capsular formulations of curcumin demonstrate low systemic bioavailability. We aimed to determine if curcumin levels were higher in healthy volunteers and cancer patients with microgranular curcumin that allows for transmucosal absorption and identify a consistent biomarker. Patients and Methods: Eight healthy volunteers and 15 HNSCC patients completed the trials. Serum levels of curcumin were measured by HPLC. Biological activity of curcumin was assessed with Multiplex Immunoassay and immunohistochemistry. Results: We achieved higher serum levels of curcumin compared to trials using capsular formulation. In cancer patients a significant decrease in expression of fibroblast growth factor-2 (FGF-2) in post-biopsy samples and decreased serum levels of FGF- 2, granulocyte macrophage colony-stimulating factor (GMCSF) and interleukin-17 (IL-17) (p<0.05) was observed. Conclusion: Transmucosal administration of microgranular curcumin leads to enhanced curcumin bioavailability that is associated with significant biological effects.",
keywords = "Bioavailability, Curcumin, Head and neck squamous cell carcinoma, Microgranules",
author = "Brian Latimer and Oleksandr Ekshyyan and Neil Nathan and Tara Moore-Medlin and Xiaohua Rong and Xiaohui Ma and Alok Khandelwal and Christy, {Hunter T.} and Fleurette Abreo and Gloria McClure and Vanchiere, {John A.} and Gloria Caldito and Tammy Dugas and Kenneth McMartin and Timothy Lian and Vikas Mehta and Nathan, {Cherie Ann O}",
year = "2015",
month = "12",
day = "1",
language = "English (US)",
volume = "35",
pages = "6411--6418",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Enhanced systemic bioavailability of curcumin through transmucosal administration of a novel microgranular formulation

AU - Latimer, Brian

AU - Ekshyyan, Oleksandr

AU - Nathan, Neil

AU - Moore-Medlin, Tara

AU - Rong, Xiaohua

AU - Ma, Xiaohui

AU - Khandelwal, Alok

AU - Christy, Hunter T.

AU - Abreo, Fleurette

AU - McClure, Gloria

AU - Vanchiere, John A.

AU - Caldito, Gloria

AU - Dugas, Tammy

AU - McMartin, Kenneth

AU - Lian, Timothy

AU - Mehta, Vikas

AU - Nathan, Cherie Ann O

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background/Aim: Curcumin is a promising nutraceutical for chemoprevention of head and neck squamous cell carcinoma (HNSCC). Capsular formulations of curcumin demonstrate low systemic bioavailability. We aimed to determine if curcumin levels were higher in healthy volunteers and cancer patients with microgranular curcumin that allows for transmucosal absorption and identify a consistent biomarker. Patients and Methods: Eight healthy volunteers and 15 HNSCC patients completed the trials. Serum levels of curcumin were measured by HPLC. Biological activity of curcumin was assessed with Multiplex Immunoassay and immunohistochemistry. Results: We achieved higher serum levels of curcumin compared to trials using capsular formulation. In cancer patients a significant decrease in expression of fibroblast growth factor-2 (FGF-2) in post-biopsy samples and decreased serum levels of FGF- 2, granulocyte macrophage colony-stimulating factor (GMCSF) and interleukin-17 (IL-17) (p<0.05) was observed. Conclusion: Transmucosal administration of microgranular curcumin leads to enhanced curcumin bioavailability that is associated with significant biological effects.

AB - Background/Aim: Curcumin is a promising nutraceutical for chemoprevention of head and neck squamous cell carcinoma (HNSCC). Capsular formulations of curcumin demonstrate low systemic bioavailability. We aimed to determine if curcumin levels were higher in healthy volunteers and cancer patients with microgranular curcumin that allows for transmucosal absorption and identify a consistent biomarker. Patients and Methods: Eight healthy volunteers and 15 HNSCC patients completed the trials. Serum levels of curcumin were measured by HPLC. Biological activity of curcumin was assessed with Multiplex Immunoassay and immunohistochemistry. Results: We achieved higher serum levels of curcumin compared to trials using capsular formulation. In cancer patients a significant decrease in expression of fibroblast growth factor-2 (FGF-2) in post-biopsy samples and decreased serum levels of FGF- 2, granulocyte macrophage colony-stimulating factor (GMCSF) and interleukin-17 (IL-17) (p<0.05) was observed. Conclusion: Transmucosal administration of microgranular curcumin leads to enhanced curcumin bioavailability that is associated with significant biological effects.

KW - Bioavailability

KW - Curcumin

KW - Head and neck squamous cell carcinoma

KW - Microgranules

UR - http://www.scopus.com/inward/record.url?scp=84949460184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949460184&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 6411

EP - 6418

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -